GI Dynamics, Inc. Announces the Appointment of Medical Device Industry Veteran Michael D. Dale as President & Chief Executive Officer
GI Dynamics to Present at the 34th Annual Canaccord Genuity Growth Conference
Appendix 4C Quarterly Report
Quarter ended 30 June 2014
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE